santarus inc (SNTS:NASDAQ GS)

Executive Profile*

Background*

Dr. Wendell D. Wierenga, Ph.D. served as an Executive Vice President of Research & Development at Santarus, Inc., since January 2007. Dr. Wierenga was a Consultant of Neurocrine Biosciences Inc., of Ambit Biosciences Corporation from December 21, 2006 to 2008. He has over 30 years of global pharmaceutical experience. He served as Executive Vice President of Research and Development of Neurocrine Biosciences Inc., from September 1, 2003 to December 21, 2006, where he ... managed a portfolio of six clinical programs including five INDs and two NDAs. Dr. Wierenga served as the Chief Executive Officer of Takeda San Diego, Inc. from September 2000 to August 2003. Dr. Wierenga served as Vice President of Med-Tech Ventures, Inc. of Warner-Lambert from 1992 to 2000. He served as a Senior Vice President, Worldwide Pharmaceutical Sciences, Technologies and Development for the Parke-Davis Pharmaceutical Research division of Warner-Lambert Company, a subsidiary of Pfizer Inc., from February 1999 to August 2001 and Senior Vice President of Research of Parke-Davis from 1990 to February 1999 and where he was responsible for worldwide drug development, including toxicology, pharmacokinetics/drug metabolism, chemical development, pharmaceutics, clinical supplies, information systems, and technology acquisition. He served as the Senior Vice President, Preclinical Research, Development and Technologies for the Pharmaceutical Research Division of Parke-Davis. He was responsible for the successful integration of Agouron and Parke-Davis R&D and for the management of 25 biotechnology corporate partnerships exceeding $750 million in pre-commercialization value. Dr. Wierenga served the Executive Director of Discovery Research of Upjohn Pharmaceuticals, where he held a succession of research and development positions from 1974 to 1990. He served as the Vice Chairman of Ambit Biosciences Corporation. He has been a Director of Cytokinetics, Incorporated since February 10, 2011 and Onyx Pharmaceuticals, Inc. since December 1996. He has been an Independent Director of Xenoport Inc. since 2000. He serves as a Director of Takeda San Diego Inc. He has been a Member of Life Sciences Strategy Advisory Board of Agilent Technologies Inc., since February 4, 2003. He has been a Member of Therapeutic Advisory Board at aTyr Pharma Inc. since March 1, 2011. He serves as a Member of Product Advisory Board of Concert Pharmaceuticals, Inc. He served as a Director of Vermillion, Inc. from 2002 to June 7, 2006 and Aurora Biosciences Corp. since October 2000. He served on the board of Directors of GenVec Inc., and Ambit Biosciences Corporation. He serves on the scientific advisory board for Ferring Pharmaceuticals Research Institute. Dr. Wierenga has been an Adjunct Professor in the Department of Chemistry at the University of Michigan since 1997. He led/participated in the research and development of more than 60 Investigational New Drugs (INDs), over 10 New Drug Applications (NDAs) and over 10 marketed products, including Lipitor(R) and Neurontin(R). He has published more than 55 original articles, 100 abstracts and invited lectures, and is a primary inventor on 30 patents. Dr. Wierenga holds a B.A. from Hope College in Holland, Michigan, a Ph.D. in Chemistry from Stanford University and an American Cancer Society Postdoctoral Fellowship at Stanford.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
SNTS:US	$21.91 USD	+0.64

COMPETITOR COMPENSATION